Geffer Effervescent Granules 24 Sachets 5 g

Geffer Effervescent Granules is an over-the-counter medicine based on Metoclopramide. Useful for treating i symptoms of hyperacidity (excess acid in the stomach), abnormal presence of air and gas in the stomach and digestive difficulties.

Geffer counters i symptoms of hyperacidity (pain and heartburn) even when accompanied by slowing of gastric transit (slow digestion). Reduces nausea, aerophagia and meteorism.

INDICATIONS

Why is Geffer Effervescent Granules 24 Sachets 5 g used? What is it for?

Symptomatic treatment of hyperacidity (pain and heartburn), when accompanied by slowing of gastric transit, nausea, aerophagia and meteorism.

ACTIVE INGREDIENTS AND EXCIPIENTS

What is the composition of Geffer Effervescent Granules 24 Sachets 5 g?

Composition

Each sachet of effervescent granules contains: active ingredients: metoclopramide hydrochloride 5 mg, dimethicone 50 mg, potassium citrate 94.45 mg, citric acid 670 mg, tartaric acid 152 mg, sodium bicarbonate 1050 mg.

Excipients

Orange flavour, sucrose

DOSAGE

How to take Geffer Effervescent Granules 24 Sachets 5 g?

1 sachet in half a glass of water before meals or at the onset of symptoms, 2-3 times a day. Do not exceed the recommended doses: elderly patients in particular must adhere to the minimum dosages indicated above. The use of the product is limited to adult patients.

CONTRAINDICATIONS AND SIDE EFFECTS

When should Geffer Effervescent Granules 24 Sachets 5 g not be used and what side effects can it cause?

Contraindications

Hypersensitivity to any of the active substances or excipients. Patients suffering from glaucoma, pheochromocytoma, epileptic disease, Parkinson's disease and other established extrapyramidal diseases or undergoing therapy with anticholinergics. Cases in which the stimulation of intestinal motility may prove dangerous, for example in the presence of gastrointestinal haemorrhage, perforation, mechanical obstruction. Patients suffering from Porphyria. Children under 16 years old. Pregnancy and breastfeeding ((see the section "Can Geffer Effervescent Granules 24 Sachets 5 g be used during pregnancy and breastfeeding?")).

Side effects

The following side effects may occur following the use of Geffer: • With frequency: rare ≥1/10,000, less than 1/1,000 Systemic disorders: Fatigue Endocrine disorders: Hypertensive crises, sometimes with fatal outcome, have been reported in patients with pheochromocytoma; therefore the use of Geffer is contraindicated in these patients. Following the use of the product, in relation to the prolactin secretion-promoting activity of metoclopramide, the following may occur: hyperprolactinemia, menstrual cycle disorders, galactorrhea and gynecomastia in men. Nervous system disorders: Drowsiness, tiredness, dizziness and extrapyramidal reactions of various types, usually dystonic, have been reported with the use of metoclopramide. They may include facial spasms, trismus, extra-ocular muscle spasms with oculogyric crises, abnormal head positions; these reactions usually regress 24 hours after stopping treatment. The development of tardive dyskinesia, potentially irreversible, has been reported in some elderly patients treated for prolonged periods; therefore, in elderly patients, therapies that last longer than 3 days should be absolutely avoided. Metabolism and nutrition disorders: Cases of porphyria have been reported • With unknown frequency (frequency cannot be estimated from the available data) Nervous system disorders: Neuroleptic malignant syndrome ((see section "What are the warnings of Geffer Effervescent Granules 24 Sachets 5 g?")) Vascular disorders: Transient increase in blood pressure Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetti-reazione-avversa.

INTERACTIONS

Which medicines or foods can modify the effect of Geffer Effervescent Granules 24 Sachets 5 g?

The sedative effects of metoclopramide are enhanced by alcohol. Anticholinergics and morphine derivatives antagonize the effect of metoclopramide on intestinal motility. The sedative effects of CNS depressant drugs (morphine derivatives, hypno-inducers, anxiolytics, sedative antihistamines, sedative antidepressants, barbiturates, etc.) and of metoclopramide are enhanced. The association of metoclopramide with drugs inducing extrapyramidal effects such as phenothiazines, butyrophenones and thioxanthenes should be avoided (in particular the activity of phenothiazines is increased, regardless of the appearance or strengthening of extrapyramidal effects). It increases the effects of MAOIs, sympathomimetics, tricyclic antidepressants. Due to the prokinetic effect of metoclopramide, the absorption of some drugs may be altered. Metoclopramide may reduce the bioavailability of digoxin, while increasing the bioavailability of ciclosporin. Reduces the CNS effects of apomorphine. It reduces the bioavailability of cimetidine by an average of approximately 22%, without however causing clinically relevant consequences. Metoclopramide interacts with serotonergic drugs (e.g. selective serotonin reuptake inhibitors), increasing the risk of serotonin syndrome.

PREGNANCY AND BREASTFEEDING

Can Geffer Effervescent Granules 24 Sachets 5 g be used during pregnancy and breastfeeding?

The product must not be used during pregnancy and breastfeeding ((see the section "When should Geffer Effervescent Granules 24 Sachets 5 g not be used and what side effects can it cause?")).

WARNINGS

What are the warnings of Geffer Effervescent Granules 24 Sachets 5 g?

Warnings and precautions

Avoid the simultaneous administration of neuroleptics - phenothiazines, butyrophenones, thioxanthenes, etc. - sedatives and alcohol ((see the section "Which medicines or foods can modify the effect of Geffer Effervescent Granules 24 Sachets 5 g?")). Neuroleptic malignant syndrome has been reported with metoclopramide both as monotherapy and in combination with neuroleptics ((see the section "When should Geffer Effervescent Granules 24 Sachets 5 g not be used and what side effects can it cause?")). If symptoms of neuroleptic malignant syndrome appear, metoclopramide should be discontinued immediately and appropriate treatment instituted. The use of the product can give rise to disturbances that alter the normal state of vigilance; patients involved in driving motor vehicles or operating potentially dangerous machinery should take this into account. After a maximum of 3 days of treatment without appreciable results, consult your doctor. Elderly patients must not exceed 3 days of consecutive treatment ((see the section "When Geffer Effervescent Granules 24 Sachets 5 g should not be used and what side effects can it cause?")) and must stick to the minimum dosages indicated ((see the section "How is Geffer Effervescent Granules 24 Sachets 5 g taken?")). Important information about some excipients. This medicine contains 288 mg sodium per sachet, equivalent to 14.4% of the WHO recommended maximum daily intake of 2 g sodium per day for an adult. The medicine contains sucrose: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase isomaltase insufficiency should not take this medicine.

Overdose

Metoclopramide can induce neurodystonic-type reactions, drowsiness, disorientation, especially at plasma levels > 100 ng/ml. Dyskinesias that respond to treatment with diazepam or anticholinergics may occur. Prolonged use of metoclopramide can also cause galactorrhea and amenorrhea, linked to the stimulation of prolactin secretion.

Driving vehicles and using machinery

Metoclopramide, at high doses, can decrease the state of vigilance; this must be taken into account when driving motor vehicles or potentially dangerous machinery.

CONSERVATION

How is Geffer Effervescent Granules 24 Sachets 5 g stored?

Store at a temperature not exceeding 25°C

FORMAT

What is the format of Geffer Effervescent Granules 24 Sachets 5 g?

24 Sachets 5 g

DRUG LEGAL TEXT

Content responsibility

This sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.

Please note

The product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.

Data source: Farmadati Italia

Website: www.farmadati.it

The Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.

The Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO/IEC 27001:2017 for information security management systems.